

Pediatric Gastric Disorders: A Comprehensive Review of Diagnosis and Treatment Strategies

Nazmul MHM¹, Mohammad Abdur Rashid², Maria Noureen³, Srikumar Chakravarthi⁴

¹Graduate School of Medicine, Perdana University, Damansara Heights, 50490 Kuala Lumpur, Malaysia

²Faculty of Medicine, AIMST University, Bedong, 08100, Kedah, Malaysia

³Rawalpindi Medical University, Chamanzar Colony, Rawalpindi, Punjab 46000, Pakistan

⁴Deputy Vice Chancellor (Academic), SEGi University, Kota Damansara, Selangor, Malaysia

Abstract

Pediatric gastric disorders present a diverse range of challenges in clinical practice. This review examines the anatomy and physiology of the pediatric gastric system, outlines common gastric disorders (including GERD, peptic ulcer disease, and H. pylori infection), and discusses diagnostic modalities and treatment approaches. Emphasis is placed on evidence-based strategies to guide healthcare professionals in effectively managing pediatric patients with gastric disorders.

Introduction

Gastric disorders in pediatric patients encompass a range of conditions affecting the stomach and associated digestive system, presenting unique challenges in diagnosis and management. This comprehensive introduction provides an overview of pediatric gastric disorders, emphasizing the importance of early diagnosis and treatment to optimize outcomes for affected children. Figure 1 shows the image of endoscopic reversed atrophic type gastritis.




Figure 1. Image of endoscopic reversed atrophic type gastritis [1]

1. Overview of Pediatric Gastric Disorders

Pediatric gastric disorders refer to a diverse group of gastrointestinal conditions that affect infants, children, and

adolescents [2-8]. These disorders can arise from various causes, including infections, anatomical abnormalities, functional disturbances, and dietary factors. Understanding the spectrum of pediatric gastric disorders is essential for healthcare professionals to provide timely and effective care.

Common Pediatric Gastric Disorders Include:

- **Gastroesophageal Reflux Disease (GERD):** Characterized by the reflux of gastric contents into the esophagus, GERD is a common condition in infants and older children [2]. Symptoms may include regurgitation, vomiting, irritability, and feeding difficulties [9-17].
- **Peptic Ulcer Disease:** While less common in children compared to adults, peptic ulcers can occur in pediatric patients due to factors such as *Helicobacter pylori* infection, use of nonsteroidal anti-inflammatory drugs (NSAIDs), or underlying systemic diseases [4, 18-22].
- ***Helicobacter pylori* (H. pylori) Infection:** This bacterial infection can lead to gastritis, peptic ulcers, and even gastric malignancies in children [5]. H. pylori-related gastritis may cause abdominal pain, bloating, nausea, and other gastrointestinal symptoms.
- **Gastritis:** Inflammation of the gastric mucosa can occur due to infections, autoimmune processes, or chemical irritants [5]. Pediatric gastritis may present with epigastric pain, nausea, vomiting, or gastrointestinal bleeding.
- **Functional Gastric Disorders:** Conditions like functional dyspepsia and gastroparesis are characterized by symptoms of abdominal discomfort, early satiety, and altered gastric motility without apparent structural abnormalities [23-30].

Understanding the pathophysiology and clinical features of these disorders is crucial for accurate diagnosis and appropriate management in pediatric patients.

2. Importance of Early Diagnosis and Treatment

Timely diagnosis and intervention are critical for pediatric patients with gastric disorders to prevent complications, promote optimal growth and development, and improve quality of life [8]. The following factors underscore the significance of early diagnosis and treatment:

a. Preventing Complications:

Untreated or poorly managed gastric disorders in children can lead

Correspondence

Nazmul MHM

poorpiku@yahoo.com

to serious complications. For instance, GERD that persists untreated may result in esophageal strictures, respiratory issues like asthma exacerbations, or failure to thrive in infants.

Peptic ulcers, if left uncontrolled, can cause recurrent bleeding episodes or perforation, requiring urgent medical or surgical intervention. Early detection and treatment can mitigate these risks and minimize long-term sequelae [31-40].

b. Ensuring Adequate Growth and Nutrition:

Many pediatric gastric disorders can impair nutrient absorption and lead to malnutrition or growth delays. Chronic gastritis, for example, may affect iron absorption, resulting in iron deficiency anemia and its associated consequences on growth and cognitive development.

Effective management of gastric disorders involves optimizing nutritional support, which is crucial for the overall health and well-being of pediatric patients.

c. Enhancing Quality of Life:

Gastric disorders can significantly impact a child's quality of life, causing discomfort, pain, and disruption of daily activities.

Functional gastric disorders, in particular, can be challenging to manage and may require a multidisciplinary approach to address physical and psychosocial aspects.

Early diagnosis allows for timely implementation of strategies to alleviate symptoms, improve comfort, and enhance the child's overall quality of life.

d. Preventing Long-Term Complications:

Certain gastric disorders, such as chronic *H. pylori* infection, are associated with an increased risk of developing gastric cancer later in life. Timely eradication of *H. pylori* in affected children can reduce this long-term risk and prevent future health complications [41-43].

In summary, early diagnosis and treatment of pediatric gastric disorders are essential for preventing complications, supporting normal growth and development, enhancing quality of life, and reducing the risk of long-term health consequences.

Anatomy and Physiology of the Pediatric Gastric System

The anatomy and physiology of the pediatric gastric system exhibit unique characteristics that evolve throughout childhood and adolescence. Understanding these developmental differences is crucial for diagnosing and managing gastric disorders in pediatric patients effectively.

1. Developmental Differences in Pediatric Gastric Anatomy

The gastric anatomy of children undergoes significant changes from infancy through adolescence [9]. Key developmental differences include:

a. Size and Capacity:

In neonates and infants, the stomach is relatively smaller compared to adults in proportion to body size. As children grow, the stomach gradually increases in size and capacity to accommodate larger volumes of ingested food. By adolescence, the stomach reaches a size and shape similar to that of an adult.

b. Gastric Mucosa:

The gastric mucosa in pediatric patients is less resistant to acid injury compared to adults due to differences in mucosal thickness and protective mechanisms [10]. This makes younger children more susceptible to gastric irritation and inflammation, contributing to conditions like gastritis and peptic ulcer disease.

c. Anatomical Variations:

Pediatric patients may exhibit anatomical variations in gastric structure, such as hiatal hernias or congenital abnormalities like pyloric stenosis. These variations can impact gastric function and contribute to the development of gastric disorders.

d. Gastric Motility:

Gastric motility patterns evolve during childhood. Neonates have predominantly irregular peristalsis, which matures into coordinated contractions and relaxation with age. The rate of gastric emptying also changes, affecting digestion and absorption of nutrients. Understanding these developmental differences in gastric anatomy is essential for interpreting clinical findings, such as symptoms of gastric reflux or dysmotility, and guiding appropriate diagnostic evaluations and treatment strategies.

2. Physiological Changes in Gastric Function During Childhood

Gastric function undergoes dynamic changes as children transition from infancy to adolescence. Several physiological factors influence gastric function during childhood [11]:

a. Gastric Acid Secretion:

Neonates have relatively low gastric acid secretion, which gradually increases over the first year of life. However, the pH of gastric contents remains less acidic compared to adults during early childhood, making infants more susceptible to bacterial infections and certain gastric disorders.

b. Digestive Enzyme Production:

The production of digestive enzymes, including pepsin and lipase, increases with age as the pancreas and other digestive organs mature. This maturation enhances nutrient digestion and absorption, supporting optimal growth and development [44-50].

c. Gastric Emptying:

Gastric emptying rates vary across different age groups. Neonates and infants have slower gastric emptying times, which gradually accelerate during childhood. However, factors such as the composition of ingested food, underlying medical conditions, and medications can influence gastric motility and emptying rates.

d. Gastric Barrier Function:

The integrity of the gastric mucosal barrier evolves during childhood. In neonates and young children, the mucosal barrier may be less effective at protecting against acid and digestive enzymes, predisposing to gastric mucosal injury and inflammation.

e. Hormonal Regulation:

Hormones play a crucial role in regulating gastric function. For example, levels of gastrin, a hormone that stimulates gastric acid secretion, increase with age. Hormonal changes during puberty can further influence gastric physiology and function.

Understanding the age-related changes in gastric function is essential for interpreting symptoms, selecting appropriate diagnostic tests, and tailoring treatment approaches in pediatric patients with gastric disorders. For instance, the management of GERD in infants may differ from that in older children due to variations in gastric acid secretion and motility [51-55].

Common Gastric Disorders in Children

Gastric disorders are prevalent in pediatric populations and can significantly impact a child's health and well-being. Understanding the etiology, clinical presentation, diagnostic evaluation, and treatment approaches for common gastric disorders is essential for healthcare professionals managing pediatric patients.

A. Gastroesophageal Reflux Disease (GERD)

Definition and Epidemiology:

Gastroesophageal reflux disease (GERD) is characterized by the retrograde flow of gastric contents into the esophagus, leading to troublesome symptoms and/or complications. GERD is relatively common in infants and children, with reported prevalence rates ranging from 2% to 8% in pediatric populations [12].

Clinical Presentation:

Infants with GERD often present with frequent regurgitation, irritability, feeding difficulties, and failure to thrive. In older children, typical symptoms include heartburn, chest pain, chronic cough, and respiratory symptoms (e.g., wheezing, recurrent pneumonia).

Diagnostic Evaluation:

Diagnostic evaluation of GERD in children involves a combination of clinical history, physical examination, and specialized tests.

Diagnostic modalities may include upper gastrointestinal (GI) contrast studies, pH monitoring (including pH-impedance testing), and esophagogastroduodenoscopy (EGD) with biopsy.

Treatment Approaches:

Management of pediatric GERD includes lifestyle modifications, dietary changes, and pharmacological therapy. Lifestyle modifications may involve positional changes (e.g., keeping infants upright after feeds), smaller and more frequent feedings, and avoidance of trigger foods. Pharmacological options include acid-suppressing medications (e.g., proton pump inhibitors, H₂-receptor antagonists) and prokinetic agents to improve gastric emptying [56-60].

B. Peptic Ulcer Disease

Etiology and Risk Factors:

Peptic ulcer disease (PUD) in children is relatively uncommon but can occur due to various factors, including *Helicobacter pylori* infection, NSAID use, or underlying systemic diseases (e.g., cystic fibrosis) [13]. *H. pylori* infection is a primary cause of PUD in pediatric patients.

Symptoms and Complications:

Children with peptic ulcers may present with epigastric pain, nausea, vomiting, and occasionally, gastrointestinal bleeding (hematemesis or melena). Complications of PUD in children include perforation, gastric outlet obstruction, and iron deficiency anemia.

Diagnostic Workup:

Diagnosis of peptic ulcers in children involves clinical history, physical examination, and diagnostic tests such as *H. pylori* testing (e.g., urea breath test, stool antigen test), upper GI endoscopy with biopsy, and imaging studies (e.g., abdominal ultrasound).

Management Strategies:

Treatment of PUD in pediatric patients focuses on eradicating *H. pylori* infection using antibiotic therapy (e.g., clarithromycin-based triple therapy). Acid-suppressing medications (proton pump inhibitors) and mucosal protective agents (e.g., sucralfate) may also be used to promote ulcer healing and prevent recurrence.

C. Helicobacter pylori Infection

Pathogenesis and Transmission:

Helicobacter pylori (*H. pylori*) is a gram-negative bacterium that colonizes the gastric mucosa, leading to chronic gastritis and

peptic ulcer disease. Transmission of *H. pylori* occurs primarily through fecal-oral or oral-oral routes, with intrafamilial transmission being common [14].

Clinical Manifestations in Children:

Children infected with *H. pylori* may present with nonspecific symptoms such as abdominal pain, bloating, nausea, and decreased appetite. In some cases, *H. pylori* infection can lead to peptic ulcers, gastritis, or even gastric malignancies (rare in children).

Diagnostic Methods:

Diagnosis of *H. pylori* infection in children involves non-invasive tests such as urea breath test, stool antigen test, or serological testing. Upper GI endoscopy with biopsy remains the gold standard for confirming *H. pylori*-associated gastritis or peptic ulcer disease.

Treatment Options:

First-line treatment for *H. pylori* infection in children consists of combination antibiotic therapy (e.g., clarithromycin-based triple therapy or bismuth-based quadruple therapy) along with acid-suppressing medications (proton pump inhibitors). Successful eradication of *H. pylori* is essential to prevent recurrent gastritis or peptic ulcers.

D. Gastritis and Gastric Motility Disorders

Types and Causes:

Gastritis in children can be acute or chronic and may result from various etiologies, including *H. pylori* infection, autoimmune diseases (e.g., autoimmune gastritis), or adverse reactions to medications (e.g., NSAIDs) [15]. Gastric motility disorders encompass conditions like gastroparesis and functional dyspepsia, characterized by impaired gastric emptying or abnormal sensations in the stomach.

Clinical Features:

Children with gastritis may experience epigastric pain, nausea, vomiting, bloating, and loss of appetite. Gastric motility disorders may present with symptoms of early satiety, postprandial fullness, and upper abdominal discomfort [61].

Diagnosis and Treatment Modalities:

Diagnosis of gastritis and gastric motility disorders in children involves clinical assessment, laboratory testing (e.g., complete blood count, inflammatory markers), upper GI endoscopy with biopsy, and gastric emptying studies (e.g., scintigraphy). Treatment strategies may include acid suppression, prokinetic agents, dietary modifications, and addressing underlying causes (e.g., *H. pylori* eradication).

Diagnostic Approaches for Pediatric Gastric Disorders

Accurate diagnosis of pediatric gastric disorders is essential for implementing appropriate treatment strategies and optimizing outcomes for affected children. Diagnostic approaches encompass a combination of clinical evaluation, laboratory investigations, and radiological imaging techniques tailored to the specific needs of pediatric patients.

A. Clinical Evaluation

In pediatric patients suspected of having gastric disorders, a comprehensive clinical evaluation is essential. This evaluation involves a thorough history-taking to gather information about presenting symptoms, their duration and frequency, associated factors like dietary habits, medication use, and family history of gastrointestinal diseases. A detailed physical examination complements the history-taking by assessing vital signs, growth

parameters, abdominal tenderness, and signs of dehydration or nutritional deficiencies. Specific findings such as epigastric tenderness, abdominal distension, or signs of malnutrition can provide important clues to underlying gastric pathology.

Recognizing red flags like persistent abdominal pain, vomiting, difficulty swallowing, failure to thrive, or signs of gastrointestinal bleeding guides further diagnostic investigations and ensures timely intervention to prevent complications.

B. Laboratory Investigations

Laboratory investigations are integral to assessing pediatric patients suspected of having gastric disorders. Blood tests, including complete blood count (CBC) and serum electrolytes, aid in detecting anemia, signs of infection, or electrolyte imbalances associated with severe vomiting or dehydration. Stool studies, such as fecal occult blood testing and stool culture, are valuable for evaluating gastrointestinal bleeding and identifying infectious pathogens contributing to gastric symptoms. These diagnostic tests play a crucial role in confirming suspected diagnoses and guiding appropriate management strategies.

C. Radiological Imaging

Radiological imaging techniques are important tools in the diagnostic workup of pediatric gastric disorders. An upper gastrointestinal (GI) series, or barium swallow, is a non-invasive procedure that evaluates the anatomy and function of the upper GI tract by visualizing structures like the esophagus, stomach, and duodenum using contrast material (barium) and X-ray imaging (Figure 2). This test can detect structural abnormalities such as hiatal hernias or strictures and assess gastric motility. Endoscopic procedures, particularly esophagogastroduodenoscopy (EGD), are gold standards for diagnosing pediatric gastric disorders, allowing direct visualization of the upper GI mucosa for conditions like esophagitis, peptic ulcers, gastritis, and eosinophilic esophagitis. EGD also facilitates tissue biopsy and therapeutic interventions, making it indispensable in refractory cases or when non-invasive tests yield inconclusive results.




Figure 2. Upper gastrointestinal barium swallow A: the tumor occupies the entire length of the esophagus (preoperative); B: normal anastomosis and intrathoracic mucosa of stomach [62]

Treatment Strategies for Pediatric Gastric Disorders

Effective management of pediatric gastric disorders requires a multidimensional approach tailored to the specific diagnosis, severity of symptoms, and individual patient characteristics.

Treatment strategies encompass pharmacological interventions, lifestyle modifications, and in some cases, surgical interventions aimed at alleviating symptoms, promoting healing, and preventing complications in pediatric patients.

A. Pharmacological Management

Pharmacological management of pediatric gastric disorders involves several key strategies. Acid-suppression therapy using proton pump inhibitors (PPIs) or H₂-receptor antagonists is effective for conditions characterized by excessive acid production, such as GERD or peptic ulcer disease, by inhibiting acid secretion and promoting mucosal healing. Prokinetic agents like metoclopramide or erythromycin can enhance gastric motility and accelerate emptying, benefiting children with delayed gastric emptying or functional dyspepsia. Additionally, antibiotic treatment targeting *Helicobacter pylori* (H. pylori) infection is essential for associated gastritis, ulcers, or lymphoma, often used in combination with acid-suppressing medications to eradicate the infection and prevent disease recurrence.

B. Lifestyle Modifications

Lifestyle modifications are fundamental in managing pediatric gastric disorders. Dietary recommendations, such as thickening formula for infants with GERD or avoiding trigger foods like acidic or spicy items, play a critical role in symptom management. Behavioral changes, including smaller, more frequent meals, upright positioning after eating, and stress reduction techniques, can alleviate symptoms and enhance quality of life for children with gastric disorders like GERD or functional dyspepsia. These modifications are tailored to individual needs and can complement pharmacological therapies.

C. Surgical Interventions

Surgical interventions are considered in specific cases of pediatric gastric disorders that are refractory to conservative management or associated with complications. Indications for surgery include persistent GERD despite medical therapy, complications of peptic ulcers (e.g., perforation), or anatomical abnormalities necessitating correction (e.g., hiatal hernia). Common procedures such as fundoplication for GERD or pyloromyotomy for hypertrophic pyloric stenosis yield favorable outcomes in pediatric patients, often performed using minimally invasive techniques to reduce surgical trauma and promote quicker recovery. Careful patient selection and comprehensive preoperative and postoperative management are essential for optimizing surgical outcomes and ensuring long-term success in pediatric gastric surgery.

Special Considerations in Pediatric Gastric Disorders

Pediatric gastric disorders present unique challenges in diagnosis, treatment, and supportive care, particularly in infants, toddlers, and children. Addressing these special considerations is essential for optimizing outcomes and promoting the overall well-being of pediatric patients and their families.

A. Management in Infants and Toddlers

Unique Challenges in Diagnosis and Treatment:

Diagnosing and managing gastric disorders in infants and toddlers pose distinct challenges due to limited verbal communication and non-specific symptoms. Infants with GERD may present with frequent regurgitation, irritability, or feeding difficulties, which can be misconstrued as normal infant behaviors. Toddlers may have difficulty articulating symptoms, leading to delays in diagnosis and

treatment initiation [18].

Special considerations in management include:

- **Growth and Development:** Monitoring growth parameters (weight gain, height) is crucial in infants and toddlers with gastric disorders to detect failure to thrive or nutritional deficiencies early.
- **Feeding Strategies:** Implementing appropriate feeding strategies (e.g., thickening feeds, smaller and more frequent meals) tailored to the age and developmental stage of infants and toddlers can help manage symptoms like reflux or feeding aversion.
- **Parental Education:** Providing education and support to parents/caregivers about recognizing symptoms, implementing dietary modifications, and adhering to treatment plans is essential for optimal management.

B. Psychological Impact

Addressing Emotional and Behavioral Aspects:

Pediatric gastric disorders can have a significant impact on the emotional and behavioral well-being of affected children and their families. Chronic symptoms, dietary restrictions, and medical interventions may lead to anxiety, frustration, or behavioral changes in pediatric patients.

Healthcare providers should:

- **Assess Psychosocial Factors:** Evaluate the psychological impact of gastric disorders on children and their families, including anxiety, depression, and adjustment difficulties [19].
- **Provide Psychological Support:** Offer counseling, behavioral interventions, or referrals to pediatric psychologists or social workers to address emotional distress and promote coping strategies.
- **Educate and Empower:** Educate children and families about the nature of the gastric disorder, treatment options, and realistic expectations to reduce uncertainty and anxiety.
- **Supportive Care for Children and Families:**
- Supportive care plays a vital role in the holistic management of pediatric gastric disorders. Providing comprehensive support involves:
- **Nutritional Counseling:** Collaborate with pediatric dietitians to optimize nutrition and ensure adequate caloric intake despite dietary restrictions or feeding difficulties.
- **Multidisciplinary Team Approach:** Engage a multidisciplinary team including pediatric gastroenterologists, nutritionists, speech therapists, and developmental specialists to address complex needs comprehensively.
- **Family Education and Resources:** Offer educational resources, support groups, or community resources to empower families in managing the challenges associated with pediatric gastric disorders.

Future Directions and Research Needs in Pediatric Gastric Disorders

Advancements in the understanding and management of pediatric gastric disorders continue to evolve, driven by ongoing research and technological innovations. Future directions in this field focus on exploring emerging therapies, developing novel diagnostic tools, and addressing areas of uncertainty to improve

outcomes for children with gastric disorders.

Emerging Therapies and Diagnostic Tools

1. Biologic Therapies:

Research is exploring the potential use of biologic therapies, such as monoclonal antibodies targeting specific inflammatory pathways, for treating pediatric gastric disorders like eosinophilic esophagitis (EoE) or autoimmune gastritis. Biologic agents offer targeted treatment options with potentially fewer systemic side effects compared to conventional immunosuppressive medications.

2. Microbiome Modulation:

Investigations into the gut microbiome's role in pediatric gastric disorders are paving the way for microbiome-targeted therapies. Probiotics and fecal microbial transplantation (FMT) hold promise for modulating gut flora and restoring microbial balance in conditions like *H. pylori* infection, gastritis, and functional gastrointestinal disorders.

3. Personalized Medicine Approaches:

Advancements in molecular diagnostics and genetic profiling enable personalized medicine approaches tailored to individual patients' genetic susceptibilities and disease mechanisms. Precision medicine strategies may optimize treatment responses and minimize adverse effects in pediatric gastric disorders.

4. Non-Invasive Diagnostic Tools:

Research is focused on developing non-invasive diagnostic tools, such as biomarker assays, breath tests, or imaging modalities (e.g., capsule endoscopy), to enhance diagnostic accuracy and minimize the need for invasive procedures like upper endoscopy in children.

5. Artificial Intelligence (AI) in Diagnostics:

Integration of AI algorithms and machine learning techniques into diagnostic processes holds potential for streamlining data analysis, improving pattern recognition, and enhancing diagnostic accuracy in pediatric gastric disorders. AI-based decision support systems may aid clinicians in making informed treatment decisions based on individual patient data.

Areas of Uncertainty in Pediatric Gastric Disorders Research

1. Long-Term Outcomes of Pediatric GERD:

Despite advances in GERD management, uncertainties remain regarding the long-term consequences of pediatric GERD, including its impact on esophageal health, respiratory outcomes, and quality of life into adulthood. Prospective studies are needed to evaluate the natural history of pediatric GERD and the efficacy of early interventions in preventing complications.

2. Optimal Management of Functional Gastric Disorders:

Functional gastrointestinal disorders, such as functional dyspepsia and cyclic vomiting syndrome, pose diagnostic and therapeutic challenges due to their multifactorial etiology and variable symptomatology. Research is needed to elucidate underlying pathophysiological mechanisms and develop effective management strategies tailored to different subtypes and age groups.

3. Role of Environmental Factors:

The influence of environmental factors (e.g., diet, exposure to toxins, socio-economic factors) on pediatric gastric disorders requires further investigation. Studies exploring gene-environment interactions and modifiable risk factors may provide insights into preventive strategies and personalized interventions.

4. Impact of Microbiome on Disease Pathogenesis:

Understanding the dynamic interplay between the gut microbiome and pediatric gastric disorders is an area of active research.

Identifying specific microbial signatures associated with disease phenotypes and responses to therapy may inform microbiome-based interventions and microbiota-targeted therapies.

5. Pediatric-Specific Therapeutic Trials:

The paucity of pediatric-specific clinical trials in gastric disorders underscores the need for dedicated research initiatives focusing on safety, efficacy, and dosing of therapeutic agents in pediatric populations. Collaborative efforts among researchers, clinicians, and regulatory agencies are essential to facilitate the development of evidence-based treatment guidelines for pediatric gastric disorders [63-65].

Conclusion

In this comprehensive review of pediatric gastric disorders, we have highlighted the diverse range of conditions affecting infants, toddlers, and children, including gastroesophageal reflux disease (GERD), peptic ulcer disease, *Helicobacter pylori* infection, gastritis, and gastric motility disorders. Diagnosis of these disorders involves a systematic approach integrating clinical evaluation, laboratory investigations (such as blood tests and stool studies), and radiological imaging techniques (such as upper GI series and endoscopic procedures) tailored to the unique needs of pediatric patients. Treatment strategies encompass pharmacological interventions, including acid-suppression therapy and prokinetic agents, alongside lifestyle modifications and, in select cases, surgical interventions to alleviate symptoms and prevent complications.

Special considerations in managing pediatric gastric disorders include the challenges of diagnosis and treatment in infants and toddlers, who may present with subtle or nonspecific symptoms. Psychological impact on affected children and families necessitates tailored psychosocial support and counseling to address emotional and behavioral aspects of living with these chronic conditions. Looking towards the future, emerging therapies like biologics and microbiome modulation hold promise for personalized medicine approaches, while advancements in non-invasive diagnostic tools and artificial intelligence (AI) integration offer potential for enhanced diagnostic accuracy and treatment efficacy.

In clinical practice, a holistic multidisciplinary approach involving pediatricians, gastroenterologists, dietitians, psychologists, and surgeons is essential to optimize care for pediatric patients with gastric disorders. Early intervention and comprehensive psychosocial support are critical for improving outcomes and quality of life. Integrating emerging research findings and innovative diagnostic tools into practice will further advance the field, addressing current uncertainties and optimizing therapeutic options for pediatric patients with gastric complaints.

Collaborative efforts among healthcare providers, researchers, and families are fundamental to advancing knowledge and implementing evidence-based strategies in the management of pediatric gastric disorders.

References

1. Kishino, Maiko, and Kouichi Nonaka. "Endoscopic features of autoimmune gastritis: focus on typical images and early images." *Journal of Clinical*

Medicine 11.12 (2022): 3523.

2. Feldman, Mark, Lawrence S. Friedman, and Lawrence J. Brandt. *Sleisenger and Fordtran's gastrointestinal and liver disease E-book: pathophysiology, diagnosis, management. Elsevier health sciences, 2015.*
3. Kumarasamy V, Anbazhagan D, Subramaniyan V, Vellasamy S. *Blastocystis sp., Parasite Associated with Gastrointestinal Disorders: An Overview of its Pathogenesis, Immune Modulation and Therapeutic Strategies. Curr Pharm Des. 2018;24(27):3172-3175.*
4. Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. *Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy. Toxicol Rep. 2021; 8:376-385.*
5. Thapa R, Afzal O, Gupta G, Bhat AA, Almalki WH, Alzarea SI, Kazmi I, Altamimi ASA, Subramaniyan V, Thangavelu L, Singh SK, Dua K. *Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer. Pathol Res Pract. 2023; 249:154736.*
6. Fuloria S, Subramaniyan V, Karupiah S, Kumari U, Sathasivam K, Meenakshi DU, Wu YS, Guad RM, Udupa K, Fuloria NK. *A Comprehensive Review on Source, Types, Effects, Nanotechnology, Detection, and Therapeutic Management of Reactive Carbonyl Species Associated with Various Chronic Diseases. Antioxidants (Basel). 2020;9(11):1075.*
7. Bhat AA, Thapa R, Goyal A, Subramaniyan V, Kumar D, Gupta S, Singh SK, Dua K, Gupta G. *Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases. Future Med Chem. 2023;15(7):583-586.*
8. Malviya R, Raj S, Fuloria S, Subramaniyan V, Sathasivam K, Kumari U, Unnikrishnan Meenakshi D, Porwal O, Hari Kumar D, Singh A, Chakravarthi S, Kumar Fuloria N. *Evaluation of Antitumor Efficacy of Chitosan-Tamarind Gum Polysaccharide Polyelectrolyte Complex Stabilized Nanoparticles of Simvastatin. Int J Nanomedicine. 2021;16:2533-2553.*
9. Chinnasamy V, Subramaniyan V, Chandiran S, Kayarohanam S, Kannian DC, Velaga VSSR, Muhammad S. *Antiarthritic Activity of Achyranthes Aspera on Formaldehyde - Induced Arthritis in Rats. Open Access Maced J Med Sci. 2019;7(17):2709-2714.*
10. Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, Samuel VP, Gubbiyappa SK, Subramaniyan V. *MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting. Pathol Res Pract. 2024;253:154991.*

11. Subramaniyan V, Shaik S, Bag A, Manavalan G, Chandiran S. Potential action of *Rumex vesicarius* (L.) against potassium dichromate and gentamicin induced nephrotoxicity in experimental rats. *Pak J Pharm Sci.* 2018;31(2):509-516.
12. Sharma VK, Sharma PP, Mazumder B, Bhatnagar A, Subramaniyan V, Fuloria S, Fuloria NK. Mucoadhesive microspheres of glutaraldehyde crosslinked mucilage of Isabgol husk for sustained release of gliclazide. *J Biomater Sci Polym Ed.* 2021;32(11):1420-1449.
13. Mukerjee N, Maitra S, Ghosh A, Subramaniyan V, Sharma R. Exosome-mediated PROTACs delivery to target viral infections. *Drug Dev Res.* 2023;84(6):1031-1036.
14. Saminathan Kayarohanam, Vetriselvan Subramaniyan, Ashok Kumar Janakiraman, Madhan Kumar S. J. Antioxidant, Antidiabetic, and Antihyperlipidemic Activities of *Dolichandrone atrovirens* in Albino Wistar rats. *Research J. Pharm. and Tech.* 2019; 12(7): 3511-3516.
15. Venkateshan S, Subramaniyan V, Chinnasamy V, Chandiran S. Anti-oxidant and anti-hyperlipidemic activity of *Hemidesmus indicus* in rats fed with high-fat diet. *Avicenna Journal of Phytomedicine.* 2016;6(5):516-25.
16. Subasini U, Thenmozhi S, Sathyamurthy D, Vetriselvan S, Victor Rajamanickam G, Dubey GP. Pharmacognostic and phytochemical investigations of *Dioscorea bulbifera* L. *International Journal of Pharmacy & Life Sciences.* 2013;4(5).
17. Vetriselvan S, Subasini U, Velmurugan C, Muthuramu T, Revathy J. Anti-inflammatory activity of *Cucumis sativus* seed in carrageenan and xylene induced edema model using albino wistar rats. *Int. J. Biopharm.* 2013;4(1):34-7.
18. Huq MZ, Abdullah JY, Wong LS, Jamayet NB, Alam MK, Rashid QF, Husein A, Ahmad WM, Eusufzai SZ, Prasad S, Subramaniyan V. Clinical Applications of Artificial Intelligence and Machine Learning in Children with Cleft Lip and Palate-A Systematic Review. *International Journal of Environmental Research and Public Health.* 2022;19(17):10860.
19. Puri A, Mohite P, Maitra S, Subramaniyan V, Kumarasamy V, Uti DE, Sayed AA, El-Demerdash FM, Algahtani M, El-kott AF, Shati AA. From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability. *Biomedicine & Pharmacotherapy.* 2024;170:116083.
20. De Rubis G, Paudel KR, Raju Allam VS, Malya V, Subramaniyan V, Singh SK, Panth N, Gupta G, Hansbro PM, Chellappan DK, Dua K. Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles. *Pathology-Research and Practice.* 2023.
21. Prem P, Naveenkumar S, Kamaraj C, Ragavendran C, Priyadharsan A, Manimaran K, Alharbi NS, Rarokar N, Cherian T, Sugumar V, Thiruvengadam M. *Valeriana jatamansi* root extract a potent source for biosynthesis of silver nanoparticles and their biomedical applications, and photocatalytic decomposition. *Green Chemistry Letters and Reviews.* 2024;17(1):2305142.
22. Naveenkumar S, Kamaraj C, Prem P, Raja RK, Priyadharsan A, Alrefaei AF, Govindarajan RK, Thamarai R, Subramaniyan V. Eco-friendly synthesis of palladium nanoparticles using *Zaleya decandra*: Assessing mosquito larvicidal activity, zebrafish embryo developmental toxicity, and impacts on freshwater sludge worm *Tubifex tubifex*. *Journal of Environmental Chemical Engineering.* 2024;12(2):111912.
23. Azad AK, Sulaiman WM, Almoustafa H, Dayoob M, Kumarasamy V, Subramaniyan V, Alshehri JM, Khan AA. A dataset of microstructure features of electro-hydrodynamic assisted 5-fluorouracil-grafted alginate microbeads and physicochemical properties for effective colon targeted carriers drug delivery. *Data in Brief.* 2024:110202.
24. Sharma A, Sharma C, Sharma L, Wal P, Mishra P, Sachdeva N, Yadav S, Vargas De-La Cruz C, Arora S, Subramaniyan V, Rawat R, Behl T, Nandave M. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis. *Can J Physiol Pharmacol.* 2024. doi: 10.1139/cjpp-2023-0259. Epub ahead of print. PMID: 38334084.
25. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, Wong LS. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. *Frontiers in Pharmacology.* 2024;15:1331062.
26. Mohite P, Yadav V, Pandhare R, Maitra S, Saleh FM, Saleem RM, Al-malky HS, Kumarasamy V, Subramaniyan V, Abdel-Daim MM, Uti DE. Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy. *ACS Omega.* 2024.
27. Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya, Riya Thapa, Archana Gahtori, Moyad Shahwan, Vikas Jakhmola, Abhishek Tiwari, Mahish Kumar, Harish Dureja, Sachin Kumar Singh, Kamal Dua, Vinoth

- Kumarasamy, Vetrivelan Subramaniyan. *CircRNAs: Pivotal modulators of TGF- β signalling in cancer pathogenesis*. *Non-coding RNA Research*, 2024.
28. Azad AK, Lai J, Sulaiman WM, Almoustafa H, Alshehade SA, Kumarasamy V, Subramaniyan V. *The Fabrication of Polymer-Based Curcumin-Loaded Formulation as a Drug Delivery System: An Updated Review from 2017 to the Present*. *cancer cells*. 2017;69:1290-9.
 29. Nag S, Mitra O, Tripathi G, Adur I, Mohanto S, Nama M, Samanta S, Gowda BH, Subramaniyan V, Sundararajan V, Kumarasamy V. *Nanomaterials-assisted Photothermal Therapy for Breast Cancer: State-of-the Advances and Future Perspectives*. *Photodiagnosis and Photodynamic Therapy*. 2024;103959.
 30. Dhar J, Hazra A, Patra R, Kumar V, Subramaniyan V, Kumarasamy V, Mitra A, Sayed A, Aleya L, El-Demerdash F, Almutairi M. *Unveiling Curvularia tuberculata-induced leaf anomalies in Rhododendron ferrugineum: implications in cultural-ecological conservation and harnessing microbial intervention in socio-economic advancement*. *Frontiers in Microbiology*. 2023;14.
 31. Al Quwatli L, Lee MF, Wu YS, Poh CL, Batumalaie K, Ahemad N, Fuloria NK, Fuloria S, Sekar M, Subramaniyan V, Sarke MR. *Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line*. *Revista Brasileira de Farmacognosia*. 2024;1-9.
 32. Alharbi HM, Alqahtani T, Alamri AH, Kumarasamy V, Subramaniyan V, Babu KS. *Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: a novel front in ovarian cancer precision therapeutics*. *Frontiers in Pharmacology*. 2024;14:1276209.
 33. Mohamad Sobri WB, Naing NN, Wan-Arfah N, Abdullah S, Subramaniyan V, Wong LS, Selvaraj S. *Prevalence and factors associated with excessive daytime sleepiness among Malaysian medical students*. *Electron J Gen Med*. 2024; 21 (2): em571.
 34. Thapa R, Goyal A, Gupta G, Bhat AA, Singh SK, Subramaniyan V, Sharma S, Prasher P, Jakhmola V, Singh SK, Dua K. *Recent developments in the role of protocatechuic acid in neurodegenerative disorders*. *EXCLI journal*. 2023;22:595.
 35. Gupta G, Hussain MS, Thapa R, Dahiya R, Mahapatra DK, Bhat AA, Singla N, Subramaniyan V, Rawat S, Jakhmola V, Dua K. *Hope on the horizon: Wharton's jelly mesenchymal stem cells in the fight against COVID-19*. *Regenerative medicine*. 2023;18(9):675-8.
 36. Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR, Gupta G, Rajakumari V, Chinni SV, Ramachawolran G, Saleh FM. *Development of new drug candidate for the inhibition of Lassa virus glycoprotein and nucleoprotein by modification of Evodiamine as Promising Therapeutic Agents*. *Frontiers in Microbiology*.;14:1206872.
 37. Rarokar NR, Saoji SD, Deole NV, Gaikwad M, Pandey A, Kamaraj C, Chinni SV, Subramaniyan V, Ramachawolran G, Dharashivkar S. *Preparation and formula optimization of cephalixin loaded transferosomal gel by QbD to enhance the transdermal delivery: In vitro, ex vivo and in vivo study*. *Journal of Drug Delivery Science and Technology*. 2023;89:104968.
 38. Rizwi FA, Abubakar M, Puppala ER, Goyal A, Bhadrawamy CV, Naidu VG, Roshan S, Tazneem B, Almalki WH, Subramaniyan V, Rawat S. *Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer*. *Journal of Environmental Pathology, Toxicology and Oncology*. 2023;42(4).
 39. Mujafarkani N, Ahamed FM, Babu KS, Debnath S, Sayed AA, Albadrani GM, Al-Ghadi MQ, Kumarasamy V, Subramaniyan V, Kamaraj C, Abdel-Daim MM. *Unveiling a novel terpolymer-metal complex: A detailed exploration of synthesis, characterization, and its potential as an antimicrobial and antioxidant agent*. *Heliyon*. 2023;9(10):e20459.
 40. Gholap AD, Gupta J, Kamandar P, Bhowmik DD, Rojekar S, Faiyazuddin M, Hatvate NT, Mohanto S, Ahmed MG, Subramaniyan V, Kumarasamy V. *Harnessing nanovaccines for effective immunization— a special concern on COVID-19: facts, fidelity, and future prospective*. *ACS biomaterials science & engineering*. 2023;10(1):271-97.
 41. Subramaniyan V, Lubau NS, Mukerjee N, Kumarasamy V. *Alcohol-induced liver injury in signalling pathways and curcumin's therapeutic potential*. *Toxicology Reports*. 2023;11:355-67.
 42. Mukherjee S, Nag S, Mukerjee N, Maitra S, Muthusamy R, Fuloria NK, Fuloria S, Adhikari MD, Anand K, Thorat N, Subramaniyan V. *Unlocking exosome-based theragnostic signatures: deciphering secrets of ovarian cancer metastasis*. *ACS omega*. 2023;8(40):36614-27.
 43. Kumarasamy V, Rajamanikam A, Anbazhagan D, Atroosh WM, Azzani M, Subramaniyan V, Abdullah SR. *Systematic Review and Meta-Analysis: Epidemiology of Human Blastocystis spp. Infection in Malaysia*. *Tropical Medicine and Infectious Disease*. 2023;8(8):415.

44. Pandey A, Malviya R, Sundram S, Subramaniyan V. *Issues and Challenges in Bioinformatics Tools for Clinical Trials. Pharmaceutical industry 4.0: Future, Challenges & Application. 2023:329.*
45. Janakiraman AK, Afroze S, Chew YL, Yee YJ, Zenli C, Subramaniyan V, Kayarohanam S. *An Expedition Towards Formulating Natural Face Serum with Garcinia mangostana (Mangosteen). Current Trends in Biotechnology and Pharmacy. 2023;17(4A (Supplement)):61-9.*
46. Mukhopadhyay M, Mukherjee A, Subramaniyan V, Kumarasamy V, Sayed AA, El-Demerdash FM, Almutairi MH, Şuğan A, Dhara B, Mitra AK. *Marvels of Bacilli in soil amendment for plant-growth promotion toward sustainable development having futuristic socio-economic implications. Frontiers in microbiology. 2023;14:1293302.*
47. Ansori AN, Pratama MR, Mukerjee N, Subramaniyan V, Ramachawolran G, Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR. *Arli Aditya Parikesit, Indonesia International Institute for Life-Sciences (iL), Indonesia. Computational Drug Discovery for Emerging Viral Infections. 2023:137.*
48. Kamaraj C, Naveenkumar S, Prem P, Ragavendran C, Subramaniyan V, Al-Ghanim KA, Malafaia G, Nicoletti M, Govindarajan M. *Green synthesis and biophysical characterization of silver and palladium nanoparticles using Laureliopsis philippiana: A potent eco-friendly larvicide with negligible impact on zebrafish (Danio rerio). Journal of Asia-Pacific Entomology. 2023;26(4):102164.*
49. Santhoshkumar T, Govindarajan RK, Kamaraj C, Alharbi NS, Manimaran K, Yanto DH, Subramaniyan V, Baek KH. *Biological synthesis of nickel nanoparticles using extracellular metabolites of Bacillus Sphaericus: Characterization and vector-borne disease control applications. South African Journal of Botany. 2023;162:481-94.*
50. Wan-Arfah N, Muzaimi M, Naing NN, Subramaniyan V, Wong LS, Selvaraj S. *Prognostic factors of first-ever stroke patients in suburban Malaysia by comparing regression models. Electron J Gen Med. 2023; 20 (6): em545.*
51. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP, Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H, Subramaniyan V, Chinni SV, Ramachawolran G. *Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. Journal of Biomolecular Structure and Dynamics. 2023:1-6.*
52. Singh AK, Malviya R, Sundram S, Subramaniyan V. *Big data in oncology: Extracting knowledge from machine learning. In Big Data in Oncology: Impact, Challenges, and Risk Assessment 2023 (pp. 77-104). River Publishers.*
53. Singla M, Verma S, Thakur K, Goyal A, Sharma V, Sharma D, Porwal O, Subramaniyan V, Behl T, Singh SK, Dua K. *From Plants to Therapies: Exploring the Pharmacology of Coumestrol for Neurological Conditions. Current medicinal chemistry. 2024.*
54. Alhussiney K, Othman R, Wei C, Abdullah I, Subramaniyan V. *In silico Discovery of RfO3 Inhibitors Against Pancreatic Ductal Adenocarcinoma via Molecular Docking, Molecular Dynamics Simulations, and ADMET Prediction. Malaysian Journal of Medicine & Health Sciences. 2024 Jan 3;20.*
55. Debnath S, Elgorban AM, Bahkali AH, Eswaramoorthy R, Verma M, Syed A, Subramaniyan V, Kamaraj C, Wong LS, Kumarasamy V. *Enhancing drought tolerance in cauliflower (Brassica oleracea var. botrytis) by targeting LFY transcription factor modulation via the ethylene precursor, ACCA: an innovative computational approach. Frontiers in Plant Science. 2024 Feb 28;15:1255979.*
56. Amin Z, Alkhatibi HA, Subramaniyan V, Alreemi RM, Husn M, Fayaz W, Thatsananchalee P, Khalid A, Shah SA, Wadood A. *Therapeutic Potential of 6-Amino Flavone: A Novel Approach for Diabetes and Inflammation via TNF- α /p-IRS Signaling Pathway in Albino Mice.*
57. Lai J, Azad AK, Sulaiman WM, Kumarasamy V, Subramaniyan V, Alshehade SA. *Alginate-Based Encapsulation Fabrication Technique for Drug Delivery: An Updated Review of Particle Type, Formulation Technique, Pharmaceutical Ingredient, and Targeted Delivery System. Pharmaceutics. 2024 Mar 6;16(3):370.*
58. Subramaniyan V. *Therapeutic importance of castor seed oil. In Nuts and Seeds in Health and Disease Prevention 2020 Jan 1 (pp. 485-495). Academic Press.*
59. Rani S, Sharma U, Deshmukh MP, Kumar V, Sharma KC, Malik MK, Subramaniyan V. *Immunomodulatory and AntiOxidant Potential of Polyherbal Dhatryadi Rasayana in the Form of Churna and Granules. ACS Omega. 2024 Mar 19;9(13):14781-90.*
60. Dh HS, Sultana R, Prabhu A, Pavan SR, Mohanto S, Subramaniyan V. *Biomedicine and pharmacotherapeutic effectiveness of combinatorial atorvastatin and quercetin on diabetic nephropathy: An in vitro study. Biomedicine & pharmacotherapy= Biomedecine & pharmacotherapie.;174:116533.*
61. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP,

Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H, Subramaniyan V, Chinni SV, Ramachawolran G. Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. *Journal of biomolecular structure & dynamics.*:1-6.

62. Niu, Zhong-Xi, et al. "Successful resection of esophageal carcinosarcoma in presence of right aortic arch: A case report."
63. Subramaniyan V. *Therapeutic Importance of Caster Seed Oil. In Nuts and Seeds in Health and Disease Prevention 2020* (pp. 485-495). Academic Press.
64. Sharma N, Zahoor I, Sachdeva M, Subramaniyan V, Fuloria S, Fuloria NK, Naved T, Bhatia S, Al-Harrasi A, Aleya L, Bungau S. Deciphering the role of nanoparticles for management of bacterial meningitis: an update on recent studies. *Environmental Science and Pollution Research.* 2021 Nov 1:1-8.
65. Varni, James W., et al. "Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases." *The Journal of pediatrics* 166.1 (2015): 85-90.